Preclinical Activity of VX-787, a First-in-Class, Orally Bioavailable Inhibitor of the Influenza Virus Polymerase PB2 Subunit

VX-787 is a novel inhibitor of influenza virus replication that blocks the PB2 cap-snatching activity of the influenza viral polymerase complex. Viral genetics and X-ray crystallography studies provide support for the idea that VX-787 occupies the 7-methyl GTP (m(7)GTP) cap-binding site of PB2. VX-7...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Antimicrob Agents Chemother
Главные авторы: Byrn, Randal A., Jones, Steven M., Bennett, Hamilton B., Bral, Chris, Clark, Michael P., Jacobs, Marc D., Kwong, Ann D., Ledeboer, Mark W., Leeman, Joshua R., McNeil, Colleen F., Murcko, Mark A., Nezami, Azin, Perola, Emanuele, Rijnbrand, Rene, Saxena, Kumkum, Tsai, Alice W., Zhou, Yi, Charifson, Paul S.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society for Microbiology 2015
Предметы:
Antiviral Agents
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4325764/
https://ncbi.nlm.nih.gov/pubmed/25547360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.04623-14
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы